Transitioning from Degarelix to Lupron can cause a dangerous PSA flare that needs to be avoided by adding an anti-androgen drug like Casodex prior to making the transition; not unlike when Lupron is started as an initial treatment.
More than a majority of cancer patients do not understand that if they enter into a clinical trial they have no guarantee that they will receive the investigational treatment that they believe their doctor wants them to receive! More transparent clinical trial consenting procedures need to be immediately instituted.
Medicare Open Enrollment starts on October 15th. If you are on Medicare this short period can be very important for your health.
Over time Gleason Scores have changed. Older Gleason grades are under-scored compared to today and about 20% of prostate cancer biopsies have major errors. The need for second biopsy patholoy opinions is vital.
Zytiga And Prednisone Provide Significant Benefits Beyond Survival With Newly Diagnosed Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
Even a doctor can face a poorly made cancer diagnosis as well as patronizing and resistant physicians. Dr. Sajjad Iqbal faced both and won.
Medicare will now cover the out patient hospital costs of HIFU as a primary treatment for prostate cancer.
Increased Levels of IL-35 in the Blood Could Serve as a Good Diagnostic Indicator for Initial Prostate Cancer Diagnosis and Staging
The current standard of care for men with non-metastatic prostate cancer who are on hormone therapy (ADT) does not include the use of any of the bisphosphonate drugs. Some men might benefit by using them at this stage.
We are lacking adequate numbers of and reliable prognostic tools to guide our treatment decisions. There needs to be a commitment to increasing research across all cancers to develop these needed tools.
It is the same drug, but it has different names. How does this happen?
The Department of Defense Prostate Cancer Research Program is seeking Cancer Thrivers to participate as peer reviewers who will select which prostate cancer research programs will receive funding.
Do you want to participate as a reviewer?
Cancer ABCs opposes the proposed Senate healthcare legislation.
The gold standard of clinical trial end points is survival. Since prostate cancer tends to move relatively slowly it can take many years for a clinical trial to be completed. We need better surrogate endpoints for survival so that trials can be completed more quickly allowing new drugs to flow to us.
The genetic test Prolaris has been approved for Medicare reimbursement for men with intermittent prostate cancer.